The ERK inhibitor SCH772984 significantly alleviated colorectal tumor growth induced by OSBPL2 knockdown, with reduced average tumor weights and volumes by 41.19% and 39.24%, respectively (Fig. 9B–D). Here, OSBPL2 is linked to neoplasm.